The present disclosure relates to methods for the treatment of multiple myeloma in patients who have one or more cytogenetic alterations. In particular, the disclosure provides methods for treatment of multiple myeloma in patients who have one or more cytogenetic alternations by administering to a patient a treatment regimen comprising a proteasome inhibitor or a pharmaceutically acceptable salt, stereoisomeric or tautomeric form thereof if said patient is identified as a likely responder to the treatment regimen by assessing the presence of said cytogenetic alterations.